SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical rises on reporting 14% surge in Q3 consolidated net profit

03 Feb 2025 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 1766.10, up by 23.40 points or 1.34% from its previous closing of Rs. 1742.70 on the BSE.

The scrip opened at Rs. 1775.00 and has touched a high and low of Rs. 1787.65 and Rs. 1735.70 respectively. So far 16921 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1960.20 on 30-Sep-2024 and a 52 week low of Rs. 1376.75 on 04-Jun-2024.

Last one week high and low of the scrip stood at Rs. 1822.15 and Rs. 1693.65 respectively. The current market cap of the company is Rs. 417004.42 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.59% and 8.93% respectively.

Sun Pharmaceutical Industries has reported 63.74% rise in its net profit at Rs 1181.05 crore for Q3FY25 as compared to Rs 721.31 crore for the same quarter in the previous year. Total income of the company increased by 21.54% at Rs 6260.20 crore for Q3FY25 as compared to Rs 5150.55 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 13.61% rise in its net profit at Rs 2917.54 crore for the quarter ended December 31, 2024, as compared to Rs 2568.03 crore for the same quarter in the previous year. Total income of the company increased by 11.96% at Rs 14141.08 crore for Q3FY25 as compared to Rs 12630.90 crore for the corresponding quarter previous year.


Sun Pharma Inds. Share Price

1847.30 12.90 (0.70%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×